Oncology Archives - WuXi Biology

Simultaneous In Vitro Profiling of Anticancer Efficacy and Toxicity

Many oncology drug candidates with promising preclinical activity ultimately fail because safety liabilities emerge too late in development. An integrated...

EpCAM-CD3 BsAb-Encoding mRNA Suppresses Lung Tumors

Bispecific antibodies have emerged as an important modality in oncology, although their broader application can be limited by manufacturing complexity...

Synthetic-Lethality Screening with PARP1 inhibition

PARP1 plays a central role in DNA repair and is a well-established target across multiple cancer types. Understanding the vulnerabilities...

Drug-Resistant KRAS G12D Lung Cancer Models

KRAS G12D inhibitors continue to advance, but treatment resistance remains an important challenge. Understanding how that resistance develops is critical...

HPV18 Tumor Models for Cancer Vaccines and Immunotherapy

OncoWuXi Express will continue to keep you informed of updates to our online pharmacology model database (OncoWuXi Database) and our...

Defining the Next Era of Cancer Therapeutics

Building on the momentum of AACR 2026, WuXi AppTec was honored to host an outstanding group of regional industry leaders...

Defining the Next Era of Cancer Therapeutics

Building on the momentum of AACR 2026, WuXi AppTec was honored to host an exceptional group of regional industry leaders...

Targeting ER Mutations and Drug Resistance

Targeting ER Mutations and Drug Resistance: R&D Strategies and Comprehensive Preclinical Evaluation of Novel ER Degraders Introduction Estrogen receptor (ER)-positive...